Yuhan Corp. posted a fourth-quarter operating profit of 26.1 billion won, swinging to profit and largely meeting market expectations, driven by strong pharmaceuticals sales and milestone payments from China.
#YonhapInfomax #YuhanCorp #OperatingProfit #Q4Results #Pharmaceuticals #MilestonePayments #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=105008
Yuhan Corp. Swings to Profit in Q4 With Operating Income of 26.1 Billion Won, Largely in Line With Expectations
Yuhan Corp. posted a fourth-quarter operating profit of 26.1 billion won, swinging to profit and largely meeting market expectations, driven by strong pharmaceuticals sales and milestone payments from China.
Yuhan Corp. to Cancel Treasury Shares Worth 36.2 Billion Won to Enhance Shareholder Value
Yuhan Corp. will cancel treasury shares worth 36.2 billion won ($27.7 million) to boost shareholder value, aligning with its multi-year capital return plan.
Yuhan Corp. and Johnson & Johnson's Janssen Korea have agreed to jointly promote the Leclaza–Rybrevant combination therapy for first-line treatment of EGFR-mutant non-small cell lung cancer in South Korea, leveraging strong Phase 3 trial results to expand market access and awareness among healthcare professionals.
#YonhapInfomax #YuhanCorp #JohnsonAndJohnson #Leclaza #Rybrevant #NonSmallCellLungCancer #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=90019
Yuhan Corp. and Johnson & Johnson Launch Joint Domestic Promotion for 'Leclaza–Rybrevant' Combination Therapy
Yuhan Corp. and Johnson & Johnson's Janssen Korea have agreed to jointly promote the Leclaza–Rybrevant combination therapy for first-line treatment of EGFR-mutant non-small cell lung cancer in South Korea, leveraging strong Phase 3 trial results to expand market access and awareness among healthcare professionals.
Yuhan Corp. Reports 55.7% Drop in Q3 Operating Profit—Impact of Milestone Absence (Comprehensive)
Yuhan Corp. reported a 55.7% year-on-year drop in Q3 operating profit due to the absence of Leclaza milestone payments, with results missing market expectations.
Yuhan Corp. reported a 55.7% year-on-year drop in Q3 operating profit to KRW 24.1 billion, missing market expectations due to the absence of milestone revenue from Lazertinib, with shares falling over 3%.
#YonhapInfomax #YuhanCorp #OperatingProfit #Q3Earnings #Lazertinib #MarketExpectations #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=89350
Yuhan Corp. Reports 55.7% Drop in Q3 Operating Profit to KRW 24.1 Billion, Misses Market Expectations (Update)
Yuhan Corp. reported a 55.7% year-on-year drop in Q3 operating profit to KRW 24.1 billion, missing market expectations due to the absence of milestone revenue from Lazertinib, with shares falling over 3%.
Yuhan Corp. posts a sharp 55.7% year-on-year drop in Q3 operating profit to 24.1 billion won, falling short of market expectations and signaling earnings pressure in South Korea's pharmaceutical sector.
#YonhapInfomax #YuhanCorp #OperatingProfit #Q3Earnings #PharmaceuticalSector #EarningsMiss #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=89347
Yuhan Corp. Receives $45 Million Milestone Payment for 'Leclaza' Following Commercial Launch in China
Yuhan Corp. will receive a $45 million milestone payment from Janssen Biotech after the commercial launch of Leclaza in China, marking a key step in its global expansion strategy.
Yuhan Corp. Hosts Investment Day—Shares Vision for Subsidiaries
Yuhan Corp. hosted its 2025 Investment Day, unveiling the business status and growth strategies of five key subsidiaries, and strengthening ties with investors and industry stakeholders.
Yuhan Corp. Breaks Ground on Osong Plant—Aims to Establish Global-Standard Manufacturing Line
Yuhan Corp. has commenced construction of a new state-of-the-art manufacturing plant in Osong, aiming to boost global competitiveness with advanced production lines and expanded collaboration opportunities.
Yuhan Corp. has signed a domestic supply agreement with Huino for the AI-powered 'MEMO Cue' monitoring solution, aiming to expand its digital healthcare footprint following recent reimbursement approval.
#YonhapInfomax #YuhanCorp #Huino #MEMOCue #DigitalHealthcare #ReimbursementApproval #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=81693
Yuhan Corp. Signs Sales Agreement with Huino for 'MEMO Cue' to Bolster Digital Healthcare Competitiveness
Yuhan Corp. has signed a domestic supply agreement with Huino for the AI-powered 'MEMO Cue' monitoring solution, aiming to expand its digital healthcare footprint following recent reimbursement approval.
Yonhap Infomax News